Adalimumab, a TNFα inhibitor, is similarly under investigation for autoimmune conditions such as rheumatoid arthritis (NCT03938701) (206) and Crohn’s disease (NCT01564823) (207). This evidence concerns the gene TNF and Crohn disease.